Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 11,529 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 11,529 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the transaction, the chief financial officer directly owned 114,866 shares of the company’s stock, valued at $6,317,630. This represents a 9.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James William Rogers also recently made the following trade(s):

• On Tuesday, May 19th, James William Rogers sold 10,853 shares of Tempus AI stock. The shares were sold at an average price of $44.07, for a total transaction of $478,291.71.

Tempus AI Stock Performance

Shares of TEM opened at $58.31 on Tuesday. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The stock has a market cap of $10.47 billion, a P/E ratio of -33.90 and a beta of 3.64. The business’s 50 day moving average price is $50.14 and its 200-day moving average price is $54.80. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The company had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.24) EPS. Equities research analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently bought and sold shares of TEM. JPL Wealth Management LLC bought a new stake in shares of Tempus AI in the 3rd quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new position in Tempus AI in the fourth quarter worth about $27,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI in the third quarter worth about $38,000. Danske Bank A S bought a new stake in Tempus AI during the third quarter worth approximately $48,000. Finally, Sunbelt Securities Inc. purchased a new stake in Tempus AI during the third quarter valued at approximately $52,000. Institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TEM. Morgan Stanley lowered their price target on Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Wolfe Research started coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. HC Wainwright reduced their price objective on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research note on Monday, May 11th. BTIG Research reaffirmed a “buy” rating and issued a $80.00 target price on shares of Tempus AI in a report on Monday, June 1st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.54.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.